Tingling, Numbness, and Underlying Malignancy: A Case Report of Glioblastoma Multiforme.

Cureus

General Medicine, Dartford and Gravesham NHS Trust, Dartford, GBR.

Published: December 2024

Glioblastoma multiforme (GBM) is a World Health Organisation (WHO) grade IV glioma originating from astrocytes. It is the most common malignant primary tumour of the brain and central nervous system (CNS) and is associated with fast progression and violent local spread, with a median overall survival of approximately 15 months after diagnosis. Due to its late and varied presentation, it is often diagnosed only after it has grown considerably. The symptomatology can vary from the individual being completely asymptomatic to mild sensory or sensorimotor symptoms. The symptoms usually arise due to compression of the fibres rather than pressure on vital structures.  We discuss a case of a 72-year-old male who presented with complaints of tingling in the left upper limb for one day, improving spontaneously. A noncontrast CT head was nondiagnostic, and an MRI reported a likely metastatic lesion, and further imaging was advised. A detailed history was taken from an oncology point of view but the patient denied any weight loss, fever, recent travel, and family history of cancers. The scans were discussed at a neuroradiology multidisciplinary team (MDT) discussion an MRI with contrast was planned. After a thorough discussion and further review by neuroradiology consultants, the patient was diagnosed with a grade IV glioblastoma - a primary tumour of the brain - which was confirmed by a biopsy and immunohistochemistry. He was treated with two cycles of radiotherapy initially, followed by chemotherapy. Unfortunately, he died eight months after the start of the treatment due to a massive pulmonary embolism, complicated by nosocomial infection. This report highlights the importance of early diagnosis and treatment for patients with glioma. It also sheds light on the symptomatology and difficulties faced in the diagnosis of gliomas. Treating physicians should adopt an MDT approach in such cases and discuss the various possibilities and differentials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743905PMC
http://dx.doi.org/10.7759/cureus.76081DOI Listing

Publication Analysis

Top Keywords

glioblastoma multiforme
8
primary tumour
8
tumour brain
8
tingling numbness
4
numbness underlying
4
underlying malignancy
4
malignancy case
4
case report
4
report glioblastoma
4
multiforme glioblastoma
4

Similar Publications

Since decades after temozolomide was approved, no effective drugs have been developed. Undoubtedly, blood-brain barrier (BBB) penetration is a severe issue that should be overcome in glioblastoma multiforme (GBM) drug development. In this research, we were inspired by linezolid through structural modification with several bioactive moieties to achieve the desired brain delivery.

View Article and Find Full Text PDF

Infectious diseases, including bacterial, fungal, and viral, have once again gained urgency in the drug development pipeline after the recent COVID-19 pandemic. Tuberculosis (TB) is an old infectious disease for which eradication has not yet been successful. Novel agents are required to have potential activity against both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis (Mtb), the causative agent of TB.

View Article and Find Full Text PDF

Background: Glioblastoma Multiforme (GBM), a highly aggressive and prevalent brain cancer with a higher incidence in males, has limited treatment success due to drug resistance, inadequate targeting and penetration of cancer cells, and an incomplete understanding of its molecular pathways. GBM is a highly aggressive brain cancer with limited treatment options. This study investigates the anticancer potential of synthesized pyrazole compounds against GBM cells.

View Article and Find Full Text PDF

Glioblastoma is the most frequent and malignant primary brain tumor. Although the survival is generally dismal for glioblastoma patients, risk stratification and the identification of high-risk subgroups is important for prompt and aggressive management. The G1-G7 molecular subgroup classification based on the MAPK pathway activation has offered for the first time a non-redundant, all-inclusive classification of adult glioblastoma.

View Article and Find Full Text PDF

Glioblastoma multiforme (GBM) is a World Health Organisation (WHO) grade IV glioma originating from astrocytes. It is the most common malignant primary tumour of the brain and central nervous system (CNS) and is associated with fast progression and violent local spread, with a median overall survival of approximately 15 months after diagnosis. Due to its late and varied presentation, it is often diagnosed only after it has grown considerably.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!